Public Market Listing
600276 SSE
SSE primary exchange listing
External market data link · No third-party exchange redistribution
Assets (116 total) 116 Total Assets
0 Approved
44 Phase 3 / Filed
72 Phase 1–2 / Early
60 Diseases
Disease: All diseases (116) Non-Small Cell Lung Cancer (13) Solid Tumors (13) Breast Cancer (10) Type 2 Diabetes (10) Heart Failure (8) Chronic Kidney Disease (5) Atherosclerotic Cardiovascular Disease (5) Prostate Cancer (5) Obesity (5) Gastric Cancer (4) Atopic Dermatitis (4) Multiple Myeloma (4) Hepatocellular Carcinoma (3) Cervical Cancer (3) Psoriasis (3) Hypertension (3) Acute Ischemic Stroke (3) Non-Hodgkin Lymphoma (3) Chronic Obstructive Pulmonary Disease (2) Metastatic Castration-Resistant Prostate Cancer (2) Bladder / Urothelial Cancer (2) Chronic Spontaneous Urticaria (2) Dyslipidemia (2) Inflammatory Bowel Disease (2) Sedation of Mechanically Ventilated ICU Patients (2) Small Cell Lung Cancer (1) Nasopharyngeal Carcinoma (1) Asthma (1) Chemotherapy-Induced Thrombocytopenia (1) Parkinson's Disease (1) Hypertrophic Cardiomyopathy (1) Pancreatic Cancer (1) Paroxysmal Nocturnal Hemoglobinuria (1) Complicated Urinary Tract Infection (1) Non-Radiographic Axial Spondyloarthritis (1) Homozygous Familial Hypercholesterolemia (1) Venous Thromboembolism (1) Diffuse Large B-Cell Lymphoma (1) Gout (1) Ovarian Cancer (1) Colorectal Cancer (1) Psoriatic Arthritis (1) Eosinophilic Granulomatosis with Polyangiitis (1) Hyperlipidemia (1) Severe Hypertriglyceridemia (1) Cardiovascular Disease / Dyslipidemia (1) Postoperative Nausea and Vomiting (1) Invasive Candidiasis (1) Alzheimer's Disease (1) Bone Metastases from Solid Tumors (1) Lupus Nephritis (1) Rheumatoid Arthritis (1) Bladder Cancer (1) Diabetic Peripheral Neuropathic Pain (1) Acute Pain (1) Gram-Negative Bacterial Infections (1) Neuromuscular Blockade During General Anesthesia (1) Contrast-Enhanced MRI (1) Chemotherapy-Induced Nausea and Vomiting (1) Controlled Ovarian Stimulation (1)
Stage: All stages (116) Approved / Phase 4 (0) Phase 3 / Filed (44) Phase 2 Phase 1 / Preclinical
Quick filter: All (116) Non-Small Cell Lung Cancer (13) Solid Tumors (13) Breast Cancer (10) Type 2 Diabetes (10) Heart Failure (8)
Showing 116 of 116 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Phase 3 PD-L1 Monoclonal antibody
Non-Small Cell Lung Cancer Small Cell Lung Cancer
Phase 3 VEGFR2 Small molecule
Non-Small Cell Lung Cancer Hepatocellular Carcinoma
Phase 3 PD-1 Monoclonal antibody
Non-Small Cell Lung Cancer Cervical Cancer Hepatocellular Carcinoma Gastric Cancer Nasopharyngeal Carcinoma
Phase 3 CDK4 and CDK6 Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer Phase 3 c-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3 Small molecule
Non-Small Cell Lung Cancer Cervical Cancer
Phase 3 TSLP Monoclonal antibody
Atopic Dermatitis Chronic Obstructive Pulmonary Disease Asthma
Phase 3 PARP (poly ADP-ribose polymerase), specifically PARP-1 Small molecule
Metastatic Castration-Resistant Prostate Cancer
Phase 3 Sodium-glucose cotransporter 2 (SGLT2) Small molecule
Type 2 Diabetes Chronic Kidney Disease
Phase 3 Thrombopoietin receptor (TPO-R) Small molecule
Chemotherapy-Induced Thrombocytopenia
Phase 3 Insulin receptor / GLP-1 receptor (combination) Peptide
Phase 3 Central dopamine precursor (levodopa) and peripheral decarboxylase inhibitor (carbidopa/benserazide) Small molecule
Phase 3 Mineralocorticoid receptor Small molecule
Phase 3 Cardiac myosin (inhibitor)
Hypertrophic Cardiomyopathy
Phase 3 PSMA
Metastatic Castration-Resistant Prostate Cancer
Phase 3 KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D
Show all 116 assets (101 more) ↓ Discontinued programmes (1) Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events (143 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (22) November 2026 (3) SHR-1681 Phase 1/2 Malignant Solid Tumors Est. primary completion 2026-11 ·
NCT06737731 ·
CT.gov ↗ What to watch
HRS-1780 Phase 2 Primary Aldosteronism Est. primary completion 2026-11 ·
NCT07470983 ·
CT.gov ↗ What to watch
December 2026 (19) Est. primary completion 2026-12 ·
NCT06840002 ·
CT.gov ↗ What to watch
Est. primary completion 2026-12 ·
NCT06568094 ·
CT.gov ↗ What to watch
SHR-7787 Phase 1/2 Advanced Solid Tumors Est. primary completion 2026-12 ·
NCT06605222 ·
CT.gov ↗ What to watch
SHR-3167 Phase 2 Diabetes Mellitus, Type 2 Est. primary completion 2026-12 ·
NCT07472725 ·
CT.gov ↗ What to watch
HRS-7085 Phase 2 Adult Patients With Moderately to Severely Active Ulcerative Colitis Est. primary completion 2026-12 ·
NCT07229950 ·
CT.gov ↗ What to watch
Safiglipron (HRS-7535) Phase 2 Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity Est. primary completion 2026-12 ·
NCT06820099 ·
CT.gov ↗ What to watch
Est. primary completion 2026-12 ·
NCT06844474 ·
CT.gov ↗ What to watch
SHR-1819 Phase 3 Seasonal Allergic Rhinitis Est. primary completion 2026-12 ·
NCT07688772 ·
CT.gov ↗ What to watch
ivarmacitinib Phase 3 Psoriatic Arthritis Est. primary completion 2026-12-13 ·
NCT04957550 ·
CT.gov ↗ What to watch
Adebrelimab Phase 2 Biliary Tract Cancer Est. primary completion 2026-12-30 ·
NCT06465563 ·
CT.gov ↗ What to watch
Trastuzumab rezetecan Phase 2 HER2 Expression / Amplification in Patients With Biliary Tract Cancer Est. primary completion 2026-12-31 ·
NCT06413745 ·
CT.gov ↗ What to watch
Est. primary completion 2026-12-31 ·
NCT07719530 ·
CT.gov ↗ What to watch
Fluzoparib Phase 3 Metastatic Castration-Resistant Prostate Cancer (mCRPC) Est. primary completion 2026-12-31 ·
NCT04691804 ·
CT.gov ↗ What to watch
Trastuzumab rezetecan Phase 3 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane Est. primary completion 2026-12-31 ·
NCT05424835 ·
CT.gov ↗ What to watch
HRS-9190 Phase 3 Neuromuscular Blockade Est. primary completion 2026-12-31 ·
NCT07746726 ·
CT.gov ↗ What to watch
2027 (55) January 2027 (2) SHR-4375 Phase 1/2 Advanced Solid Tumor Est. primary completion 2027-01 ·
NCT07298772 ·
CT.gov ↗ What to watch
RSS0393 Phase 3 Plaque Psoriasis Subjects Est. primary completion 2027-01 ·
NCT07543224 ·
CT.gov ↗ What to watch
February 2027 (2) Adebrelimab Phase 1/2 Malignant Solid Tumor Est. primary completion 2027-02 ·
NCT07136142 ·
CT.gov ↗ What to watch
HRS-5346 Phase 2 Lipoprotein Disorder Est. primary completion 2027-02 ·
NCT07767513 ·
CT.gov ↗ What to watch
March 2027 (6) HRS-4642 Phase 1/2 Advanced Solid Tumors Est. primary completion 2027-03 ·
NCT06520488 ·
CT.gov ↗ What to watch
ivarmacitinib Phase 2 Non-segmental Vitiligo Est. primary completion 2027-03 ·
NCT07251595 ·
CT.gov ↗ What to watch
HRS-1893 Phase 2 Heart Failure With Preserved Ejection Fraction Est. primary completion 2027-03 ·
NCT07269717 ·
CT.gov ↗ What to watch
SHR-A1912 Phase 3 Diffuse Large B-cell Lymphoma Est. primary completion 2027-03 ·
NCT06929624 ·
CT.gov ↗ What to watch
Rezvilutamide Phase 3 Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Est. primary completion 2027-03 ·
NCT07241416 ·
CT.gov ↗ What to watch
April 2027 (2) Zeprumetostat Phase 2 Follicular Lymphoma Est. primary completion 2027-04 ·
NCT06368167 ·
CT.gov ↗ What to watch
SHR-2173 Phase 2 Primary IgA Nephropathy Est. primary completion 2027-04 ·
NCT07354932 ·
CT.gov ↗ What to watch
May 2027 (4) SHR-4375 Phase 1/2 Solid Tumors Est. primary completion 2027-05 ·
NCT06764628 ·
CT.gov ↗ What to watch
Est. primary completion 2027-05 ·
NCT07458269 ·
CT.gov ↗ What to watch
June 2027 (6) SHR-9803 Phase 1/2 Advanced Solid Tumors Est. primary completion 2027-06 ·
NCT06906731 ·
CT.gov ↗ What to watch
SHR-1819 Phase 2 Moderate-to-severe Atopic Dermatitis Est. primary completion 2027-06 ·
NCT07321951 ·
CT.gov ↗ What to watch
SHR-1139 Phase 2 Pyoderma Gangrenosum Est. primary completion 2027-06 ·
NCT07444684 ·
CT.gov ↗ What to watch
SHR-2173 Phase 2 Active Lupus Nephritis Est. primary completion 2027-06 ·
NCT07229742 ·
CT.gov ↗ What to watch
Pyrotinib Phase 3 Breast Cancer Est. primary completion 2027-06 ·
NCT03980054 ·
CT.gov ↗ What to watch
Trastuzumab rezetecan Phase 3 HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Est. primary completion 2027-06-30 ·
NCT06123494 ·
CT.gov ↗ What to watch
July 2027 (5) SHR-1139 Phase 2 Plaque Psoriasis Est. primary completion 2027-07 ·
NCT07758075 ·
CT.gov ↗ What to watch
Apatinib + Adebrelimab Phase 2 Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk Est. primary completion 2027-07 ·
NCT07682272 ·
CT.gov ↗ What to watch
SHR4640 Phase 2 Primary Gout and Hyperuricemia Est. primary completion 2027-07 ·
NCT07362355 ·
CT.gov ↗ What to watch
Retlirafusp alfa Phase 1/2 Relapsed or Advanced Non-small Cell Lung Cancer Est. primary completion 2027-07-30 ·
NCT05503888 ·
CT.gov ↗ What to watch
August 2027 (3) SHR-1139 Phase 2 Adult Patients With Moderately to Severely Active Ulcerative Colitis Est. primary completion 2027-08 ·
NCT07232576 ·
CT.gov ↗ What to watch
SHR-2173 Phase 2 Primary Membranous Nephropathy Est. primary completion 2027-08 ·
NCT07289763 ·
CT.gov ↗ What to watch
HRS-8080 Phase 3 Locally Advanced Breast Cancer, Metastatic Breast Cancer Est. primary completion 2027-08 ·
NCT07024173 ·
CT.gov ↗ What to watch
September 2027 (4) HRS-4508 Phase 2 Solid Tumor Est. primary completion 2027-09 ·
NCT07003321 ·
CT.gov ↗ What to watch
SHR-2173 Phase 2 Generalized Myasthenia Gravis Est. primary completion 2027-09 ·
NCT07622342 ·
CT.gov ↗ What to watch
SHR-1703 Phase 3 Asthma With Eosinophilic Phenotype Est. primary completion 2027-09 ·
NCT06653322 ·
CT.gov ↗ What to watch
SHR-A1904 Phase 3 Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Est. primary completion 2027-09-20 ·
NCT06649292 ·
CT.gov ↗ What to watch
October 2027 (4) Est. primary completion 2027-10 ·
NCT07140393 ·
CT.gov ↗ What to watch
Adebrelimab + HRS-4642 Phase 1/2 Locally Advanced or Metastatic Pancreatic Cancer With Est. primary completion 2027-10 ·
NCT07296341 ·
CT.gov ↗ What to watch
SHR-3167 Phase 3 Type 2 Diabetes Est. primary completion 2027-10 ·
NCT07920939 ·
CT.gov ↗ What to watch
HRS-5346 Phase 2 Lipoprotein(a) Est. primary completion 2027-10-12 ·
NCT07614984 ·
CT.gov ↗ What to watch
November 2027 (4) SHR-1139 Phase 2 Palmoplantar Pustulosis of Adults Est. primary completion 2027-11 ·
NCT07923851 ·
CT.gov ↗ What to watch
Adebrelimab Phase 2 Lung Cancer Est. primary completion 2027-11 ·
NCT07241767 ·
CT.gov ↗ What to watch
SHR-1819 Phase 3 Adolescents With Moderate-to-severe Atopic Dermatitis Est. primary completion 2027-11 ·
NCT07309055 ·
CT.gov ↗ What to watch
December 2027 (13) Adebrelimab Phase 1/2 Non-small Cell Lung Cancer (NSCLC) Est. primary completion 2027-12 ·
NCT06754930 ·
CT.gov ↗ What to watch
Adebrelimab + SHR-1501 Phase 1/2 Patients With Advanced or Metastatic Malignant Tumors Est. primary completion 2027-12 ·
NCT07073534 ·
CT.gov ↗ What to watch
Adebrelimab Phase 1/2 Solid Tumor Est. primary completion 2027-12 ·
NCT07229586 ·
CT.gov ↗ What to watch
HRS-4508 Phase 2 Lung Cancer Est. primary completion 2027-12 ·
NCT07232849 ·
CT.gov ↗ What to watch
Adebrelimab Phase 2 Advanced Esophageal Squamous Cell Carcinoma Est. primary completion 2027-12 ·
NCT07751341 ·
CT.gov ↗ What to watch
HRS-1893 Phase 2 Hypertrophic Cardiomyopathy Est. primary completion 2027-12 ·
NCT07021963 ·
CT.gov ↗ What to watch
Trastuzumab rezetecan Phase 3 Early-stage or Locally Advanced HER2-positive Breast Cancer Est. primary completion 2027-12 ·
NCT07196774 ·
CT.gov ↗ What to watch
Notiretatug rezetecan Phase 3 Recurrent Cervical Cancer, Metastatic Cervical Cancer Est. primary completion 2027-12 ·
NCT07418749 ·
CT.gov ↗ What to watch
HRS-4357 Phase 3 PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer Est. primary completion 2027-12 ·
NCT07311694 ·
CT.gov ↗ What to watch
2028 (33) January 2028 (3) SHR-3167 Phase 3 Diabetes Mellitus, Type 2 Est. primary completion 2028-01 ·
NCT07913061 ·
CT.gov ↗ What to watch
February 2028 (2) ribupatide Phase 3 Obesity, Overweight Est. primary completion 2028-02 ·
NCT07284875 ·
CT.gov ↗ What to watch
vunakizumab Phase 3 Active Non-radiographic Axial Spondyloarthritis Est. primary completion 2028-02 ·
NCT06860750 ·
CT.gov ↗ What to watch
March 2028 (4) SHR-2173 Phase 2 Systemic Lupus Erythematosus Est. primary completion 2028-03 ·
NCT07299422 ·
CT.gov ↗ What to watch
Est. primary completion 2028-03 ·
NCT07284979 ·
CT.gov ↗ What to watch
Adebrelimab + Trastuzumab rezetecan Phase 3 PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer Est. primary completion 2028-03 ·
NCT07111832 ·
CT.gov ↗ What to watch
ribupatide Phase 3 Obesity With Diabetes, Overweight With Diabetes Est. primary completion 2028-03-27 ·
NCT07284901 ·
CT.gov ↗ What to watch
April 2028 (2) Adebrelimab Phase 3 Advanced Cervical Cancer Est. primary completion 2028-04 ·
NCT07168200 ·
CT.gov ↗ What to watch
Felcorekibart Phase 3 Chronic Rhinosinusitis With Nasal Polyps Est. primary completion 2028-04 ·
NCT07132827 ·
CT.gov ↗ What to watch
May 2028 (1) June 2028 (3) Adebrelimab Phase 2 Resectable Non-small Cell Lung Cancer Est. primary completion 2028-06 ·
NCT07704645 ·
CT.gov ↗ What to watch
Trastuzumab rezetecan Phase 2 Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer Est. primary completion 2028-06 ·
NCT07497386 ·
CT.gov ↗ What to watch
September 2028 (1) SHR-1703 Phase 2 Eosinophilic Asthma Patients Est. primary completion 2028-09 ·
NCT06441812 ·
CT.gov ↗ What to watch
October 2028 (3) Adebrelimab Phase 2/3 Non-squamous Non-small Cell Lung Cancer Est. primary completion 2028-10 ·
NCT06335355 ·
CT.gov ↗ What to watch
SHR-1819 Phase 2/3 Prurigo Nodularis Est. primary completion 2028-10 ·
NCT06554509 ·
CT.gov ↗ What to watch
November 2028 (1) SHR-4298 Phase 1/2 Malignant Solid Tumors Est. primary completion 2028-11 ·
NCT07229612 ·
CT.gov ↗ What to watch
December 2028 (13) HRS-8364 Phase 1/2 Solid Tumor Est. primary completion 2028-12 ·
NCT07446153 ·
CT.gov ↗ What to watch
Est. primary completion 2028-12 ·
NCT07230106 ·
CT.gov ↗ What to watch
SHR-4849 Phase 2 Malignant Solid Tumors Est. primary completion 2028-12 ·
NCT07028281 ·
CT.gov ↗ What to watch
SHR-1703 Phase 2/3 Eosinophilic Granulomatosis With Polyangiitis Est. primary completion 2028-12 ·
NCT05979051 ·
CT.gov ↗ What to watch
Dalpiciclib + HRS-8080 Phase 3 Locally Advanced or Metastatic Breast Cancer Est. primary completion 2028-12 ·
NCT07354022 ·
CT.gov ↗ What to watch
Hetrombopag Phase 3 Patients With Chemotherapy-Induced Thrombocytopenia Est. primary completion 2028-12 ·
NCT07286032 ·
CT.gov ↗ What to watch
2029 (15) February 2029 (1) March 2029 (3) Felcorekibart Phase 2 Pulmonary Disease, Chronic Obstructive Est. primary completion 2029-03-07 ·
NCT07915791 ·
CT.gov ↗ What to watch
April 2029 (2) HRS-1780 Phase 2/3 Uncontrolled or Resistant Hypertension Est. primary completion 2029-04 ·
NCT07708441 ·
CT.gov ↗ What to watch
HRS-4642 Phase 3 KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting Est. primary completion 2029-04 ·
NCT07232875 ·
CT.gov ↗ What to watch
May 2029 (1) June 2029 (2) Est. primary completion 2029-06 ·
NCT06474455 ·
CT.gov ↗ What to watch
Plinabulin Phase 3 Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance Est. primary completion 2029-06-01 ·
NCT07361484 ·
CT.gov ↗ What to watch
July 2029 (2) Felcorekibart Phase 3 Pulmonary Disease, Chronic Obstructive Est. primary completion 2029-07-20 ·
NCT07780656 ·
CT.gov ↗ What to watch
Felcorekibart Phase 3 Pulmonary Disease, Chronic Obstructive Est. primary completion 2029-07-20 ·
NCT07780669 ·
CT.gov ↗ What to watch
September 2029 (1) December 2029 (3) Adebrelimab Phase 3 Advanced Biliary Tract Cancer Est. primary completion 2029-12 ·
NCT07229625 ·
CT.gov ↗ What to watch
Adebrelimab Phase 3 Locally Advanced Gastric or Gastroesophageal Junction Cancer Est. primary completion 2029-12 ·
NCT07522151 ·
CT.gov ↗ What to watch
SHR-1501 Phase 3 Papillary-Only Non-muscle-invasive Bladder Cancer Est. primary completion 2029-12 ·
NCT07726992 ·
CT.gov ↗ What to watch
2030 (9) April 2030 (2) Trastuzumab rezetecan Phase 3 HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Est. primary completion 2030-04 ·
NCT06126640 ·
CT.gov ↗ What to watch
HRS-1780 Phase 3 Chronic Kidney Disease Est. primary completion 2030-04 ·
NCT07419828 ·
CT.gov ↗ What to watch
June 2030 (1) Est. primary completion 2030-06 ·
NCT07424287 ·
CT.gov ↗ What to watch
October 2030 (1) Adebrelimab + Trastuzumab rezetecan Phase 3 Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma Est. primary completion 2030-10 ·
NCT07118527 ·
CT.gov ↗ What to watch
November 2030 (1) Adebrelimab + HRS-4642 Phase 3 Systemic Treatment-naïve Pancreatic Cancer Est. primary completion 2030-11-30 ·
NCT07900789 ·
CT.gov ↗ What to watch
December 2030 (4) SHR-A1904 Phase 2 Biliary Tract Cancer Est. primary completion 2030-12 ·
NCT07450976 ·
CT.gov ↗ What to watch
HRS-8080 Phase 3 Breast Cancer Est. primary completion 2030-12 ·
NCT07349069 ·
CT.gov ↗ What to watch
2031 (7) February 2031 (1) May 2031 (1) July 2031 (1) September 2031 (1) Adebrelimab Phase 3 Hepatocellular Carcinoma Est. primary completion 2031-09 ·
NCT07691762 ·
CT.gov ↗ What to watch
October 2031 (1) Adebrelimab Phase 2 Colorectal Cancer Est. primary completion 2031-10 ·
NCT07071714 ·
CT.gov ↗ What to watch
December 2031 (2) 2032 (2) November 2032 (2) Adebrelimab Phase 2/3 Locally Advanced Resectable Rectal Cancer Est. primary completion 2032-11 ·
NCT07454720 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (19) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
9 April 2027 FDA action date Camrelizumab PDUFA target action date for rivoceranib + camrelizumab (first-line uHCC) Recent
5 November 2026 Filing accepted Camrelizumab FDA accepts the resubmitted rivoceranib + camrelizumab applications (first-line uHCC) 9 October 2026 Filing submitted Apatinib Rivoceranib NDA resubmitted to the FDA after July 2026 CRL US, FDA · Elevar Therapeutics, Inc. ·
Source ↗ 24 September 2026 Topline result SHR-1701 (retlirafusp alfa) RELIGHT Phase 3 (NCT04950322) met its overall survival primary endpoint (full results in JCO) China · Jiangsu Hengrui Pharmaceuticals Co., Ltd. ·
Source ↗ 2 September 2026 Filing accepted Safiglipron (HRS-7535) NMPA accepts Hengrui's marketing application for HRS-7535 tablets in type 2 diabetes CN, NMPA · Jiangsu Hengrui Pharmaceuticals ·
Source ↗ 31 August 2026 Topline result HRS-5346 Phase 2 study of oral HRS-5346 (NCT06816264) in adults at high cardiovascular risk with elevated Lp(a) presented at ESC 2026: HRS-5346 reduced Lp(a) Jiangsu Hengrui Pharmaceuticals ·
Source ↗ 28 August 2026 Topline result SHR-1918 Phase 3 (NCT06723652) presented at ESC 2026: LDL-C 64.2% lower than placebo at week 12 24 August 2026 Filing accepted HRG2010 NMPA accepts HRG2010 capsules marketing application (Parkinson's disease), based on Phase 3 HRG2010-301 (NCT06596876) CN, NMPA · Jiangsu Hengrui Pharmaceuticals Co., Ltd. ·
Source ↗ 29 July 2026 Filing accepted SHR-A2009 NMPA accepts the ruzaltatug rezetecan (SHR-A2009) marketing application in EGFR-mutated NSCLC after EGFR TKI; Phase 3 SHR-A2009-301 (NCT06671379) met its PFS primary CN, NMPA · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (Hengrui subsidiary) ·
Source ↗ 10 July 2026 Complete response letter Apatinib FDA issues complete response letter for rivoceranib + camrelizumab NDA (first-line uHCC) US, FDA · Elevar Therapeutics, Inc. ·
Source ↗ 10 July 2026 Complete response letter Camrelizumab FDA issues complete response letter for rivoceranib + camrelizumab (first-line uHCC) US, FDA · Elevar Therapeutics, Inc. ·
Source ↗ 2 July 2026 Filing accepted Trastuzumab rezetecan NMPA accepts the marketing application for trastuzumab rezetecan in HER2-low breast cancer (CXSS2600103), with priority review China, NMPA · Jiangsu Hengrui Pharmaceuticals ·
Source ↗ 9 June 2026 Filing accepted SHR6508 NMPA accepts the NDA for HS-10568 (SHR6508) in secondary hyperparathyroidism of CKD on hemodialysis China, NMPA · Hansoh Pharmaceutical Group Company Limited ·
Source ↗ The 12 most recent of 18 past events are shown.
Financial reports Quarterly & interim (15)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2026-Q1 $1.2B $238M $5.9B — report ↗
View 14 more Annual history (5 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $4.7B $1.0B — — report ↗
Hengrui Pharmaceuticals reported revenue of $4,669M, up 19.9% YoY, with R&D spend of $1,027M, up 12.1% YoY. Net profit attributable to shareholders reached RMB 7.72 billion, up 21.8% YoY; cash and equivalents were not disclosed.
The company guided for approximately 53 innovative product and indication approvals anticipated during 2026-2028. In 2025 it secured seven Class 1 innovative drug approvals, one Class 2 approval, and six new indications, while 15 NDAs/BLAs were accepted and over 100 proprietary innovative products are in clinical development. Key events included five overseas business development deals, a strategic collaboration with GSK, and a Hong Kong listing raising HK$11.4 billion.
View 4 more years Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $3.9B $916M $3.4B — report ↗ 2023-FY $3.2B $701M $2.9B — report ↗ 2022-FY $3.2B $728M $2.2B — report ↗ 2021-FY $4.0B $921M $2.1B — report ↗